Investment Summary

L Capital Partners Invests In Evogen

On December 12, 2008, private equity firm L Capital Partners invested in technology hardware company Evogen for 3M USD

Investment Highlights
  • This is L Capital Partners’ 1st transaction in the Technology Hardware sector.
  • This is L Capital Partners’ 4th largest (disclosed) transaction.
  • This is L Capital Partners’ 13th transaction in the United States.
  • This is L Capital Partners’ 1st transaction in Missouri.

Investment Summary
Date 2008-12-12
Target Evogen
Sector Technology Hardware
Investor(s) L Capital Partners
Deal Type Venture
Deal Value 3M USD

Target

Evogen

Kansas City, Missouri, United States
Evogen is a global biological detection system company, and is the leading developer and manufacturer of High Definition PCR™ (HD PCR) molecular diagnostics systems, meeting the needs of a diverse range of markets including biodefense, clinical, research, animal health, agbio, food and water safety, indoor air quality, environmental monitoring and forensics.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

L Capital Partners

New York, New York, United States

Investor

Category Private Equity Firm
Founded 2004
PE ASSETS 165M USD
Size Small
Type Sector Focused
DESCRIPTION

L Capital Partners is a specialist private equity firm focused on investing in companies operating within the healthcare, technology, and energy/environmental sectors, looking to bring 'groundbreaking products to market'. Within healthcare, L Capital looks to invest in biopharmaceutical and medical device businesses. Within technology, the Firm's emphasis is on security/defense and IT businesses. And within the energy/environmental sector, the L Capital's focus is investing in opportunities that 'improve the quality of life'. L Capital was formed in 2004 and has offices in New York City and Tel Aviv, Israel.

DEAL STATS #
Overall 13 of 16
Sector (Technology Hardware) 1 of 1
Type (Venture) 12 of 14
State (Missouri) 1 of 1
Country (United States) 13 of 15
Year (2008) 4 of 4
Size (of disclosed) 4 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2008-10-17 CeNeRx BioPharma

Cary, North Carolina, United States

CeNeRx is a privately held clinical-stage biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system. CeNeRx's most advanced compound, a reversible inhibitor of monoamine oxidase, or RIMA, is in Phase II development for treatment resistant depression. RIMAs may have efficacy advantages over current agents for depression and are expected to have a good safety profile. The company's CNS pipeline also includes clinical-stage hypothalamic-pituitary adrenal (HPA) axis modulators for the treatment of a variety of CNS disorders including anxiety and depression; a small molecule, orally active agent for the prevention and treatment of neuropathies and neurodegenerative disorders; and a series of selective cannabinoid compounds that have successfully completed preclinical proof-of-concept studies for the treatment of pain, glaucoma and spasticity.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2009-03-01 WiSpry

Irvine, California, United States

WiSpry, Inc. is a fabless RF semiconductor company that develops RF silicon integrated circuits and components for wireless communication products.

Buy -
Mergr

Product

Company

Legal